Consistency and Dependability of Quality Testing for Clinical-Grade Induced Pluripotent Stem Cells

Time: 5:00 pm
day: Day One


  • To maximize the full potential of human-induced iPSC-based therapies, banks of suitable quality and demonstrable equivalence of iPSC lines are required for the use of different banks as starting materials for Advanced Therapy Medicinal Products (ATMPs) and the comparability of the ATMPs thereafter
  • This requires consistent quality control testing across iPSC manufacturers’ facilities worldwide
  • Here we describe data from an international quality assessment round organized by the Global Alliance of iPSC Therapies (GAiT) specifically undertaken to assess iPSC quality control assays